Sunshine Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Sunshine Biopharma Inc. on April 8, 2022. The report discloses a new employment agreement entered into with the Company's Chief Executive Officer, Dr. Steve N. Slilaty.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On April 8, 2022, the Company executed a new employment agreement with Dr. Steve N. Slilaty. Key terms include:
- Base Salary: $360,000 annually, with annual increases tied to the Consumer Price Index or 5%, whichever is higher.
- Term: Four years, with an automatic renewal for an additional three years.
- Termination Payments: $10 million payable if terminated by the Company without cause or by Dr. Slilaty for valid reason.
- Expiration Payment: $2 million payable upon the natural expiration of the agreement.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, or general risk factors. The primary contingency disclosed is the significant potential cash outflow associated with the termination or expiration of the CEO's employment agreement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for definitions of "without cause" and "valid reason."
- Assess the impact of the potential $10 million termination liability on the Company's current cash position.
- Confirm the Company's ability to fund the $2 million expiration payment upon the agreement's conclusion.